U.K. Dry Eye Syndrome Market Outlook (2018 to 2032)

Market Dynamics

Dry eye syndrome, a chronic and progressive condition, has become a priority for the U.K. health-care industry. Globally, the Dry Eye Syndrome (DES) market is expected to reach a staggering £2.2 billion by 2032 according to a report by Global Data. In the U.K., treatment and services associated with DES are expected to increase dramatically due to aging awareness and rising healthcare costs, making a comprehensive insight into the current and future market demand essential for a successful approach to its management. In terms of the current market situation in the U.K., treatments are mostly concentrated on the provision of artificial tears and anti-inflammatory agents to reduce symptoms. Ophthalmic devices and in-patient services related to DES are still in their infancy and are undeveloped in the country. In addition, the health-care system in the U.K. is typically limited in its ability to fund and provide equipment and services for such a niche market, resulting in a lack of available devices and services. The lack of effective and efficient home treatment options for DES is due to the lack of research, and complete understanding of the condition, its contributing risk factors and its effects on quality of life.

In the coming years, the U.K. is projected to experience an increase in market potential due to advancements in intraocular lenses and the availability of more comprehensive patient education resources. Improved diagnostic and management protocols are likely to be developed, which will allow for the diagnosis of more DES cases early. Consequently, the number of patients requiring treatment and services for management of DES will likely increase in the future. Advances in biotechnology and medical devices are expected to provide further avenues of progress, such as increased therapeutic accuracy of ocular drugs and devices. Improved diagnostics and treatment modalities will reduce the cost of management and enhance patient outcomes. However, cost and access to services will remain the foremost barrier to greater acceptance of treatment and management of DES in the U.K., and thus, remains an area that needs to be tackled in order to promote better treatment outcomes. In conclusion, the U.K. Dry Eye Syndrome market is expected to witness an increasing demand over the next decade as advancements in devices and treatments become available.

The presence of a large patient population with a wide array of health conditions, in addition to the lack of skilled personnel in the healthcare sector, further contribute to the potential of the market. In order to ensure better management of DES and better patient outcomes, the U.K. needs to take a comprehensive approach to the condition, creating an organized platform for diagnosis and treatment, as well as providing improved access to services.

Research Methodology

Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2023.